INCY 25 (Jakafi 25 mg)

Generic Name: ruxolitinib

Pill imprint INCY 25 has been identified as Jakafi 25 mg.

Jakafi is used in the treatment of myelofibrosis; polycythemia vera; myeloproliferative disorders and belongs to the drug class multikinase inhibitors. Risk cannot be ruled out during pregnancy. Jakafi 25 mg is not a controlled substance under the Controlled Substance Act (CSA).

Jakafi

Generic Name:

ruxolitinib

Imprint:

INCY 25

Strength:

25 mg

Color:

White

Shape:

Elliptical / Oval

Availability:

Prescription only

Drug Class:

Multikinase inhibitors

Pregnancy Category:

C - Risk cannot be ruled out

CSA Schedule:

Not a controlled drug

Manufacturer:

Incyte Corporation

More info Print Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.